RefleXion to Share Groundbreaking Research in 37 Scientific Presentations at the AAPM 2024 Annual Meeting
July 18 2024 - 10:01AM
Business Wire
Company to introduce significant product
upgrades that enable treating multiple tumors in a single treatment
plan to improve patient experience.
RefleXion Medical, an external-beam theranostic oncology
company, today announced that researchers from multiple clinical
programs will present pioneering scientific evidence in 37 oral and
poster presentations confirming the efficacy and feasibility of the
RefleXion® X1 machine with SCINTIX® biology-guided radiotherapy
(BgRT) at the 2024 American Association of Physicists in Medicine
(AAPM) Annual Meeting in Los Angeles, July 21-25.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240718915301/en/
Researchers from multiple clinical
programs will present scientific evidence in 37 oral and poster
presentations at the 2024 AAPM annual meeting, confirming the
efficacy and feasibility of the RefleXion® X1 machine with SCINTIX®
biology-guided radiotherapy. (Photo: Business Wire)
“Since last year’s AAPM, we have begun delivering SCINTIX
therapy in the clinic, which required a significant effort to
characterize and establish standards for this first-in-world
radiotherapy approach. This year, we have 37 presentations that
collectively reflect this collaborative effort between physicists,
clinicians and researchers,” said Sean Shirvani, M.D., chief
medical officer of RefleXion. “The rigor of our research, the
scientific collaboration, and the potential impact on patient care
are truly inspiring.”
The following four oral presentations and programs highlight new
research showcasing the potential of SCINTIX therapy to optimize
multi-target treatment planning with high dosimetric accuracy, the
nuances of clinical workflows, the accuracy of multi-target SCINTIX
therapy, and an introduction to BIGSTAR (Biological Image Guidance
for Spatial-Temporally Adaptive Radiotherapy), an innovative
approach that aims to enhance cancer patient management and
treatment outcomes by focusing on intra-fraction immune response to
direct adaptive radiotherapy based on tumor biology. Detailed
information on all 37 presentations may be found here.
Oral Presentations and Invited Programs:
Oral: Initial Dosimetric Performance of
Multi-Target, Multi-Treatment Area Image-Guided Radiotherapy in a
Single Session, Mason Hazlett, M.S. Sunday, July 21, 1:42 pm in
Room 152
Invited Program: PET Guided Radiation
Therapy 101, Dae Yup Han, Ph.D. Tuesday, July 23, 8:06 am in
Room 502A
Invited Program: Introduction and Overview
of Current Technology for Biology-guided RT, Dae Yup Han, Ph.D.
Thursday, July 25, 8:30 am, Room 502A
Oral: Pulsar – a Biology-guided
Radiotherapy Strategy That Optimizes Immuno-Radiotherapy Based on
Intra-Fraction Immune Response, Robert Timmerman, M.D.
Thursday, July 25, 8:44 am, Room 502A
RefleXion is also hosting an industry lunch symposium during the
AAPM annual meeting at 12:30 PM CDT on July 22. Physicists Murat
Surucu, Ph.D., Arnold Pompos, Ph.D., Tyler Watkins, Ph.D., and
David Carlson, Ph.D. will share their latest clinical experience
with SCINTIX biology-guided radiotherapy, highlight early clinical
cases and share Quality Assurance (QA) procedures and
practices.
The company will also hold interactive SCINTIX technology
demonstrations in its booth (#1407) focused on its recent product
release that includes the ability to treat multiple targets, both
SCINTIX therapy and SBRT targets, in a single treatment plan, and
the availability of live PET data during treatment delivery. The
rollout of these features, designed to improve the patient
experience and physician confidence, is currently underway at all
RefleXion installed base sites.
About RefleXion Medical
RefleXion is a privately held theranostic oncology company
located in Hayward, Calif., commercializing SCINTIX biology-guided
radiotherapy, a novel therapy that uses a single radiotracer
injection to transform cancer cells into real-time biological
beacons to control external-beam radiotherapy delivery to single or
multiple tumors. SCINTIX therapy is indicated for use in FDG-guided
treatment of lung and bone tumors arising from either primary lung
and bone cancers or resulting from metastases by other primary
cancers. In addition to SCINTIX therapy, the RefleXion X1 is also
FDA-cleared for conventional image-guided radiotherapy for solid
tumors located anywhere in the body. For more information, please
visit www.reflexion.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718915301/en/
Amy Cook acook@reflexion.com +1 925-222-5094